Literature DB >> 29735662

STXBP4 regulates APC/C-mediated p63 turnover and drives squamous cell carcinogenesis.

Susumu Rokudai1,2, Yingchun Li3, Yukihiro Otaka2, Michiru Fujieda2, David M Owens4, Angela M Christiano5, Masahiko Nishiyama2, Carol Prives1.   

Abstract

Levels of the N-terminally truncated isoform of p63 (ΔN p63), well documented to play a pivotal role in basal epidermal gene expression and epithelial maintenance, need to be strictly regulated. We demonstrate here that the anaphase-promoting complex/cyclosome (APC/C) complex plays an essential role in the ubiquitin-mediated turnover of ΔNp63α through the M-G1 phase. In addition, syntaxin-binding protein 4 (Stxbp4), which we previously discovered to bind to ΔNp63, can suppress the APC/C-mediated proteolysis of ΔNp63. Supporting the physiological relevance, of these interactions, both Stxbp4 and an APC/C-resistant version of ΔNp63α (RL7-ΔNp63α) inhibit the terminal differentiation process in 3D organotypic cultures. In line with this, both the stable RL7-ΔNp63α variant and Stxbp4 have oncogenic activity in soft agar and xenograft tumor assays. Notably as well, higher levels of Stxbp4 expression are correlated with the accumulation of ΔNp63 in human squamous cell carcinoma (SCC). Our study reveals that Stxbp4 drives the oncogenic potential of ΔNp63α and may provide a relevant therapeutic target for SCC.

Entities:  

Keywords:  APC/C; STXBP4; p53; p63; squamous cell carcinoma

Mesh:

Substances:

Year:  2018        PMID: 29735662      PMCID: PMC6003458          DOI: 10.1073/pnas.1718546115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

1.  p63 is a p53 homologue required for limb and epidermal morphogenesis.

Authors:  A A Mills; B Zheng; X J Wang; H Vogel; D R Roop; A Bradley
Journal:  Nature       Date:  1999-04-22       Impact factor: 49.962

2.  STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma.

Authors:  Yukihiro Otaka; Susumu Rokudai; Kyoichi Kaira; Michiru Fujieda; Ikuko Horikoshi; Reika Iwakawa-Kawabata; Shinji Yoshiyama; Takehiko Yokobori; Yoichi Ohtaki; Kimihiro Shimizu; Tetsunari Oyama; Jun'ichi Tamura; Carol Prives; Masahiko Nishiyama
Journal:  Clin Cancer Res       Date:  2017-01-13       Impact factor: 12.531

3.  The expression of p63 during epidermal remodeling in psoriasis.

Authors:  Chun-Shen Shen; Tatsuya Tsuda; Shinji Fushiki; Hitoshi Mizutani; Kiyofumi Yamanishi
Journal:  J Dermatol       Date:  2005-04       Impact factor: 4.005

4.  Differential expression of p63 isoforms in normal tissues and neoplastic cells.

Authors:  Karin Nylander; Borek Vojtesek; Rudolf Nenutil; Britta Lindgren; Göran Roos; Wang Zhanxiang; Björn Sjöström; Ake Dahlqvist; Philip J Coates
Journal:  J Pathol       Date:  2002-12       Impact factor: 7.996

5.  p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes.

Authors:  M Dohn; S Zhang; X Chen
Journal:  Oncogene       Date:  2001-05-31       Impact factor: 9.867

Review 6.  p63: oncogene or tumor suppressor?

Authors:  Alea A Mills
Journal:  Curr Opin Genet Dev       Date:  2005-12-15       Impact factor: 5.578

7.  The regulation of Cdc20 proteolysis reveals a role for APC components Cdc23 and Cdc27 during S phase and early mitosis.

Authors:  S Prinz; E S Hwang; R Visintin; A Amon
Journal:  Curr Biol       Date:  1998-06-18       Impact factor: 10.834

Review 8.  p63: Molecular complexity in development and cancer.

Authors:  Matthew D Westfall; Jennifer A Pietenpol
Journal:  Carcinogenesis       Date:  2004-03-19       Impact factor: 4.944

9.  The E3 ubiquitin ligase Itch controls the protein stability of p63.

Authors:  Mario Rossi; Rami I Aqeilan; Michael Neale; Eleonora Candi; Paolo Salomoni; Richard A Knight; Carlo M Croce; Gerry Melino
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-14       Impact factor: 11.205

10.  Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer.

Authors:  Balázs Győrffy; Pawel Surowiak; Jan Budczies; András Lánczky
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

View more
  12 in total

1.  Distinct interactors define the p63 transcriptional signature in epithelial development or cancer.

Authors:  Rosalba Pecorari; Francesca Bernassola; Gerry Melino; Eleonora Candi
Journal:  Biochem J       Date:  2022-06-30       Impact factor: 3.766

2.  Biomarker discovery for practice of precision medicine in hypopharyngeal cancer: a theranostic study on response prediction of the key therapeutic agents.

Authors:  Yumiko Kawata-Shimamura; Hidetaka Eguchi; Reika Kawabata-Iwakawa; Mitsuhiko Nakahira; Yasushi Okazaki; Tetsuya Yoda; Reidar Grénman; Masashi Sugasawa; Masahiko Nishiyama
Journal:  BMC Cancer       Date:  2022-07-16       Impact factor: 4.638

3.  Elucidation of WW domain ligand binding specificities in the Hippo pathway reveals STXBP4 as YAP inhibitor.

Authors:  Rebecca E Vargas; Vy Thuy Duong; Han Han; Albert Paul Ta; Yuxuan Chen; Shiji Zhao; Bing Yang; Gayoung Seo; Kimberly Chuc; Sunwoo Oh; Amal El Ali; Olga V Razorenova; Junjie Chen; Ray Luo; Xu Li; Wenqi Wang
Journal:  EMBO J       Date:  2019-11-29       Impact factor: 11.598

4.  Genetic loci and metabolic states associated with murine epigenetic aging.

Authors:  Khyobeni Mozhui; Ake T Lu; Caesar Z Li; Amin Haghani; Jose Vladimir Sandoval-Sierra; Yibo Wu; Robert W Williams; Steve Horvath
Journal:  Elife       Date:  2022-04-07       Impact factor: 8.713

Review 5.  ΔNp63 in squamous cell carcinoma: defining the oncogenic routes affecting epigenetic landscape and tumour microenvironment.

Authors:  Veronica Gatti; Claudia Fierro; Margherita Annicchiarico-Petruzzelli; Gerry Melino; Angelo Peschiaroli
Journal:  Mol Oncol       Date:  2019-03-22       Impact factor: 6.603

Review 6.  TP63 links chromatin remodeling and enhancer reprogramming to epidermal differentiation and squamous cell carcinoma development.

Authors:  Mei Yi; Yixin Tan; Li Wang; Jing Cai; Xiaoling Li; Zhaoyang Zeng; Wei Xiong; Guiyuan Li; Xiayu Li; Pingqing Tan; Bo Xiang
Journal:  Cell Mol Life Sci       Date:  2020-05-23       Impact factor: 9.261

Review 7.  Distinct p63 and p73 Protein Interactions Predict Specific Functions in mRNA Splicing and Polyploidy Control in Epithelia.

Authors:  Julian M Rozenberg; Olga S Rogovaya; Gerry Melino; Nickolai A Barlev; Alexander Kagansky
Journal:  Cells       Date:  2020-12-25       Impact factor: 6.600

8.  Mutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling.

Authors:  Eisuke Horigome; Michiru Fujieda; Tadashi Handa; Ayaka Katayama; Masashi Ito; Ami Ichihara; Daiki Tanaka; Navchaa Gombodorj; Shinji Yoshiyama; Arito Yamane; Keiichi Yamada; Jun Horiguchi; Kazuo Shinozuka; Tetsunari Oyama; Masahiko Nishiyama; Susumu Rokudai
Journal:  Oncotarget       Date:  2018-10-02

Review 9.  The role of Anaphase Promoting Complex activation, inhibition and substrates in cancer development and progression.

Authors:  Cordell VanGenderen; Troy Anthony Alan Harkness; Terra Gayle Arnason
Journal:  Aging (Albany NY)       Date:  2020-08-15       Impact factor: 5.682

10.  Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine.

Authors:  Erkhem-Ochir Bilguun; Kyoichi Kaira; Reika Kawabata-Iwakawa; Susumu Rokudai; Kimihiro Shimizu; Takehiko Yokobori; Tetsunari Oyama; Ken Shirabe; Masahiko Nishiyama
Journal:  BMC Cancer       Date:  2020-09-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.